Cardioprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors: What Have We Learned So Far?

By afschroeder • August 5, 2026

Qi L, Wright EM, Cai X. Cardioprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors: What Have We Learned So Far? JACC Adv. 2026 Aug 4;5(9):103095. doi: 10.1016/j.jacadv.2026.103095. Epub ahead of print. PMID: 42551341.

Tags: Cardiology/Epi, cardioprotective effect, cardiovacular disease, heart failure, Post Doc, Publications, sodium-glucose cotransporter-2 inhibitor

Related Posts

Artificial intelligence-derived splenic response in cardiac positron emission tomography is associated with major adverse cardiovascular events: a multi-site study

Ramirez G, Dharmavaram NL, Shanbhag A, Miller RJH, Kavanagh PB, Yi J, Lemley M, Builoff V, Marcinkiewicz A, Dey D, Hainer J, Wopperer S, Knight[...]

Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial

Neely J, Yao J, Kudo M, Finn RS, Sangro B, Melero I, El-Khoueiry AB, Yau T, Harding JJ, Rosmorduc O, Tschaika M, Novosiadly R, Cruz[...]

Deep learning-enabled screening of chronic kidney disease from echocardiography

Yuan V, Ieki H, Sandhu A, Nguyen LH, Cheng PP, Chang ST, Ambrosy AP, Kwan AC, Go AS, Cheng S, Ouyang D. Deep learning-enabled screening[...]